Letter: Grant Funding Chances

Regarding the item entitled "Eye Institute Offers Best Odds For Success" (Funding Briefs, The Scientist, Oct. 30, 1989, page 23), I would like to bring to your attention a crucial omission. The statements regarding award rates are undoubtedly correct; however, they do not note that the award rate percentages include noncompeting continuations. It concerns me that our legislators might read this article and assume that there is a 30% chance of a new grant being funded at NIH. That is particular

Written byJudy Emery
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Regarding the item entitled "Eye Institute Offers Best Odds For Success" (Funding Briefs, The Scientist, Oct. 30, 1989, page 23), I would like to bring to your attention a crucial omission.

The statements regarding award rates are undoubtedly correct; however, they do not note that the award rate percentages include noncompeting continuations. It concerns me that our legislators might read this article and assume that there is a 30% chance of a new grant being funded at NIH. That is particularly worrisome, given the current budget situation, but it would be worrisome even without the current situation.

One of our investigators pointed out this article to me and expressed his concern. I hope that future references to NIH award rates will clarify just what is included in the rate.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies